Articles related to CLINICAL TRIALS

Discover why CPX-351 extends relapse-free survival but does not significantly alter overall survival in younger AML/MDS patients, as revealed by the UK NCRI AML19 trial.

Discover how STRIDE is setting new benchmarks in the treatment of unresectable hepatocellular carcinoma, offering both improved survival rates and a tolerable safety profile.

Discover how SABR is setting a new standard in the treatment of inoperable renal cell carcinoma, offering exceptional cancer control with minimal side effects.

The FDA’s recent concerns about NurOwn’s efficacy and manufacturing consistency could have far-reaching implications for the future of ALS treatment. Stay updated as the agency’s final decision is expected in December.

Ulotaront’s failure to meet its primary endpoint in recent phase 3 trials raises questions about the drug’s future and emphasizes the need for more effective treatments in the field of schizophrenia.

Discover how MDMA-assisted therapy is setting new benchmarks in PTSD treatment, offering clinically meaningful improvements and a strong safety profile.